Patent ID: 8802129

Claim:
A method for treating an ocular condition, the method comprising the steps of: a) inserting an implant into an ocular site of a patient with an ocular condition, the implant comprising an active agent and a carrier associated with the active agent; b) releasing substantially all of the active agent from the implant; c) obtaining an improvement in the ocular condition at a time when a therapeutic amount of the active agent is not present at the ocular site; and d) maintaining the improvement in the ocular condition for an extended period of time during which the therapeutic amount of the active agent is not present at the ocular site; wherein the carrier comprises a 30/10 w/w mixture of hydrophilic end PLGA and hydrophobic end PLGA, wherein the active agent is ranibizumab, wherein the implant is formed by an extrusion method, and wherein the ocular condition is macular degeneration.